Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR115 in relapsed/refractory NHL or advanced solid tumors
NCT05650580Phase 1Recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TR115 in Non-Hodgkin lymphoma (NHL) and solid tumor, sponsored by Tarapeutics Science Inc. Primary endpoints: Adverse events and serious adverse events, dose limited toxicities and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
TR115
03
Conditions
Non-Hodgkin lymphoma (NHL)solid tumor
Beyond the preview
Go deeper on NCT05650580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650580.